Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005300PMC
http://dx.doi.org/10.7189/jogh.11.03052DOI Listing

Publication Analysis

Top Keywords

lebanon losing
4
losing front
4
lebanon
1
front
1

Similar Publications

Paranasal sinus mucoceles are benign, expansile lesions that most commonly affect the frontal sinus with less frequent ethmoid sinus involvement. The most common presentation of these lesions is nasal or orbital symptoms due to their anatomical proximity to critical structures. Vestibular symptoms such as dizziness are exceedingly rare and unreported in the literature as a primary presentation of ethmoid mucoceles.

View Article and Find Full Text PDF

Iron is an essential nutrient and a constituent of ferroproteins and enzymes crucial for human life. Generally, nonmenstruating individuals preserve iron very efficiently, losing less than 0.1% of their body iron content each day, an amount that is replaced through dietary iron absorption.

View Article and Find Full Text PDF

COVID-19 hit Lebanon at the worst time, amid an economic downward spiral and national protests regarding living conditions and political corruption. The first case was found on February 21, 2020, and the first batch of vaccines arrived on March 24, 2021. Although neither natural infection nor mass vaccination truly provided herd immunity, the latter was a more effective way to handle the pandemic, and Lebanon fell short on that path.

View Article and Find Full Text PDF

Background: Low pre-albumin, body mass index, and thiamine levels have been associated with poor nutritional status and cognitive/memory deficits in adult heart failure patients. However, the relationship of these nutritional/dietary intake biomarkers to cognition has not been assessed in adolescents post-Fontan procedure and healthy controls.

Methods: This is a cross-sectional study.

View Article and Find Full Text PDF
Article Synopsis
  • - In June 2021, the FDA granted controversial accelerated approval for aducanumab, a drug for Alzheimer's, based on an unverified measure (beta-amyloid) and without clear clinical benefits.
  • - A survey of 214 physicians revealed that 86% would not prescribe aducanumab, and 67% lost trust in other drugs approved through the FDA's accelerated program due to this decision.
  • - As new Alzheimer's treatments, like lecanemab (approved in January 2023), emerge, the findings highlight the potential negative impact of FDA decisions on physicians' trust and prescribing habits.
View Article and Find Full Text PDF